Edgewell Personal Care heads into its May 8 Q2 earnings release with short sellers holding a notably large position — and the options market firmly tilted toward protection.
Short interest is the most prominent feature of the setup. Nearly 12% of EPC's free float is currently sold short, a level that ranks the stock in the bottom 13th percentile of its universe on that measure. The position jumped roughly 22% over the past month, driven by a sharp step-up in mid-April when shares short climbed from around 4.5 million to nearly 5.9 million within a single session on April 10. Since then, short interest has retreated slightly — down about 1.7% on the week — but remains materially elevated. The borrow market tells a different story, however: cost to borrow is just 0.42% APR, and availability is ample, suggesting the large short position is not under squeeze pressure heading into the event.
Options positioning reinforces the defensive lean without amplifying it. The put/call ratio at 1.64 is almost exactly in line with its 20-day average of 1.64, giving a z-score near zero — so while puts dominate outright, there has been no fresh rush for downside protection ahead of the print. The PCR has actually eased from above 1.80 in early April to its current level, meaning the options market has become marginally less hedged even as short interest climbed. That divergence is worth noting: short sellers have added exposure, but options traders have not piled on.
The analyst debate reflects a stock priced for caution. The mean price target from coverage amounts to roughly $24, about 8% above the current $22.39. The bull case centres on gross margin resilience — management has guided for around 10 basis points of gross margin expansion even as it absorbs tariff costs, alongside an EBITDA forecast of $334 million that suggests the business remains operationally stable. Bears focus on North American volume erosion: net sales in the region fell 4% in the most recent quarter, with weakness across Wet Shave, Feminine Care, and Sun Care. Tariff headwinds add another layer of margin uncertainty, and persistent reinvestment needs are keeping EBIT and free cash flow growth constrained. Recent analyst moves — the most current available, from February 2026 — were largely target raises after the February print, with Wells Fargo lifting to $22 and Barclays to $21, both maintaining unchanged ratings. That limits the signal value; no major firm has moved since.
One piece of genuine encouragement for bulls sits in the factor scores: EPC ranks in the 96th percentile for EPS surprise, meaning the company has a strong track record of exceeding estimates. The single prior earnings reaction available — a 1.2% one-day dip followed by a 6.5% recovery over five days after the February 2026 print — is consistent with a stock that tends to absorb initial disappointment and find buyers. The EV/EBITDA multiple is running around 9x, up modestly over the past month, while the P/E near 11.5x remains undemanding relative to the broader consumer staples space.
Tomorrow's print will test whether volume trends in North America are stabilising or deteriorating further — and whether the company's margin framework can hold against tariff drag at a price level that has recovered 27% year-to-date from its lows.
See the live data behind this article on ORTEX.
Open EPC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
